Purpose: We investigated the long-term oncological and functional outcome of nephron-sparing surgery/partial nephrectomy (PN) versus radical nephrectomy (RN) for any renal cell carcinoma (RCC) ≥4 cm. Patients and Methods: Between 1997 and 2013, we identified 128 patients undergoing PN for RCC ≥4 cm and matched this collective to 128 patients undergoing RN. We then compared overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS) and functional parameters in both groups. The median follow-up time was 58 months (3-210 months). Results: Compared to RN, patients with a PN showed a significantly higher 10-year OS (77.0 vs. 63.0%, p = 0.04), CSS (90.6 vs. 71.7%, p = 0.002) and PFS (82.9 vs. 57.4%, p ≤ 0.001). Renal function preservation was better in the PN group (24 months estimated glomerular filtration rate: 68.2 ml/min for PN vs. 40.6 ml/min for RN, p ≤ 0.01) with significantly less new onset chronic kidney diseases. Total complication rate was comparable, whereas PN procedures showed more Clavien-Dindo grade I + II complications, portraying the technical challenge of PN in larger RCCs. Conclusions: Whenever feasible, PN should be considered for renal masses ≥4 cm, as this technique shows better long-term results regarding disease-specific survival and renal function preservation in our study group.

Keywords:
Nephron-sparing surgery, Nephrectomy, Matched-pair, Large renal mass, Large renal tumour, Renal cell carcinoma
1.
Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC: EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398-406.
2.
Robson CJ: Radical nephrectomy for renal cell carcinoma. J Urol 1963;89:37-42.
3.
Novick AC: Partial nephrectomy for renal cell carcinoma. Urol Clin North Am 1987;14:419-433.
4.
Zini L, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Antebi E, Saad F, Patard JJ, Montorsi F, Karakiewicz PI: Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 2009;115:1465-1471.
5.
Hadjipavlou M, Khan F, Fowler S, Joyce A, Keeley FX, Sriprasad S: Partial vs radical nephrectomy for T1 renal tumours: an analysis from the British association of urological surgeons nephrectomy audit. BJU Int 2016;117:62-71.
6.
Patard JJ, Pantuck AJ, Crepel M, Lam JS, Bellec L, Albouy B, et al: Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication. Eur Urol 2007;52:148-154.
7.
Thompson RH, Siddiqui S, Lohse CM, Leibovich BC, Russo P, Blute ML: Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol 2009;182:2601-2606.
8.
Campbell SC, Novick AC: Expanding the indications for elective partial nephrectomy: is this advisable? Eur Urol 2006;49:952-954.
9.
Leibovich BC, Blute M, Cheville JC, Lohse CM, Weaver AL, Zincke H: Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;171:1066-1070.
10.
Badalato GM, Kates M, Wisnivesky JP, Choudhury AR, McKiernan JM: Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach. BJU Int 2012;109:1457-1462.
11.
Jang HA, Kim JW, Byun SS, Hong SH, Kim YJ, Park YH, Yang KS, Cho S, Cheon J, Kang SH: Oncologic and functional outcomes after partial nephrectomy versus radical nephrectomy in T1b renal cell carcinoma: a multicenter, matched case-control study in Korean patients. Cancer Res Treat 2016;48:612-620.
12.
Roos FC, Brenner W, Müller M, Schubert C, Jäger WJ, Thüroff JW, Hampel C: Oncologic long-term outcome of elective nephron-sparing surgery versus radical nephrectomy in patients with renal cell carcinoma stage pT1b or greater in a matched-pair cohort. Urology 2011;77:803-808.
13.
Larcher A, Capitanio U, Terrone C, Volpe A, De Angelis P, Dehó F, Fossati N, Dell'Oglio P, Antonelli A, Furlan M, Simeone C, et al: Elective nephron sparing surgery decreases other cause mortality relative to radical nephrectomy only in specific subgroups of patients with renal cell carcinoma. J Urol 2016;pii:S0022-5347(16)30508-0.
14.
Shuch B, Hanley J, Lai J, Vourganti S, Kim SP, Setodji CM, Dick AW, Chow WH, Saigal C: Overall survival advantage with partial nephrectomy: a bias of observational data? Cancer 2013;119:2981-2989.
15.
Weight CJ, Lieser G, Larson BT, Gao T, Lane BR, Campbell SC, et al: Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol 2010;58:293-298.
16.
Kaushik D, Kim SP, Childs MA, Lohse CM, Costello BA, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH: Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol 2013;64:600-606.
17.
Iizuka J, Kondo T, Hashimoto Y, Kobayashi H, Ikezawa E, Takagi T, et al: Similar functional outcomes after partial nephrectomy for clinical T1b and T1a renal cell carcinoma. Int J Urol 2012;19:980-986.
18.
Kim SP, Murad MH, Thompson RH, Boorjian SA, Weight CJ, Han LC, et al: Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol 2012;188:51-57.
19.
Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, et al: A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011;59:543-552.
20.
Thompson RH, Leibovich BC, Lohse CM, Zincke H, Blute ML: Complications of contemporary open nephron sparing surgery: a single institution experience. J Urol 2005;174:855-858.
21.
Gill IS, Matin SF, Desai MM, Kaouk JH, Steinberg A, Mascha E, et al: Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol 2003;170:64-68.
22.
Hafez KS, Fergany AF, Novick AC: Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999;162:1930-1933.
23.
Lane BR, Campbell SC, Gill IS: 10-year oncologic outcomes after laparoscopic and open partial nephrectomy. J Urol 2013;190:44-49.
24.
Papalia R, Simone G, Ferriero M, Guaglianone S, Costantini M, Giannarelli D, et al: Laparoscopic and robotic partial nephrectomy without renal ischaemia for tumours larger than 4 cm: perioperative and functional outcomes. World J Urol 2012;30:671-676.
25.
Sutherland SE, Resnick MI, Maclennan GT, Goldman HB: Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter? J Urol 2002;167:61-64.
26.
Thompson RH, Frank I, Lohse CM, Saad IR, Fergany A, Zincke H, Leibovich BC, Blute ML, Novick AC: The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. J Urol 2007;177:471-476.
27.
Kriegmair MC, Pfalzgraf D, Häcker A, Michel MS: ZIRK-technique: zero ischemia resection in the kidney for high-risk renal masses: perioperative outcome. Urol Int 2015;95:216-222.
28.
Trehan A: Comparison of off-clamp partial nephrectomy and on-clamp partial nephrectomy: a systematic review and meta-analysis. Urol Int 2014;93:125-134.
29.
Hew MN, Baseskioglu B, Barwari K, Axwijk PH, Can C, Horenblas S, Bex A, Rosette JJ, Pes MP: Critical appraisal of the PADUA classification and assessment of the R.E.N.A.L. nephrometry score in patients undergoing partial nephrectomy. J Urol 2011;186:42-46.
30.
Okhunov Z, Rais-Bahrami S, George AK, Waingankar N, Duty B, Montag S, Rosen L, Sunday S, Vira MA, Kavoussi LR: The comparison of three renal tumor scoring systems: C-index, P.A.D.U.A., and R.E.N.A.L. nephrometry scores. J Endourol 2011;25:1921-1924.
31.
Altunrende F, Laydner H, Hernandez AV, Autorino R, Khanna R, White MA, Isac W, Spana G, Hillyer S, Yang B, Yakoubi R, Haber GP, Kaouk JH, Stein RJ: Correlation of the RENAL nephrometry score with warm ischemia time after robotic partial nephrectomy. World J Urol 2013;31:1165-1169.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.